We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Amicus Therapeutics Inc | NASDAQ:FOLD | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.12 | -1.15% | 10.30 | 10.19 | 10.75 | 10.79 | 10.36 | 10.74 | 1,360,422 | 01:00:00 |
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01.
|
Other Events.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
Exhibit No.
|
Description
|
Press Release dated June 25, 2018 titled "Amicus Therapeutics Announces European Regulatory and Clinical Updates for AT-GAA in Pompe Disease".
|
|
AMICUS THERAPEUTICS, INC.
|
Date: June 26, 2018
|
By: /s/ Ellen S. Rosenberg
|
|
Name: Ellen S. Rosenberg
|
|
Title: General Counsel and Corporate Secretary
|
1 Year Amicus Therapeutics Chart |
1 Month Amicus Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions